This American Pharmacists Month, XiFin Pharmacy Solutions invites pharmacy professionals to join the 2025 Pharmacy Transformation Study, which aims to identify key success factors shaping the future of pharmacy care.…
CEL-SCI Corporation (NYSE American: CVM) today highlighted the promising implications for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) following a recent meeting of the U.S. Food and Drug Administration (FDA) Oncologic…
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on innovative treatments for neuropsychiatric disorders, announced today that its Phase 2b trial of ALTO-100 for major depressive disorder (MDD)…
GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare’s…
Oscar Health, Inc. (NYSE: OSCR), a healthcare technology leader, announced today that it will expand its offerings in the ACA marketplace in 2025. This move aims to provide more individuals,…
Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part…
Agilent Technologies Inc. (NYSE: A) has unveiled its next-generation Agilent InfinityLab LC Series, featuring the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems,…
Proteintech Genomics, a leader in antibody-based multiplexed solutions for single-cell multiomics, has announced the launch of its MultiPro® Human Discovery Panel. This innovative antibody panel is designed to revolutionize single-cell…
Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today encouraging topline results from the one-year Phase IV ELEVATUM study. This open-label, single-arm trial evaluated Vabysmo® (faricimab-svoa)…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, recently shared encouraging outcomes from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab, a monoclonal antibody aimed at preventing…
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that Health Canada has granted marketing authorization for DAYBUE™ (trofinetide) to treat Rett syndrome in patients aged two and older. This approval, under…
Airway Therapeutics, Inc. has announced the launch of a multinational Phase 3 clinical trial for zelpultide alfa (rhSP-D). This study aims to prevent bronchopulmonary dysplasia (BPD) and mitigate lung injury…